KPC Cell Line (C57/BL6 genetic background)
Syngeneic pancreatic ductal adenocarcinoma (PDA) cell line from the KPC mouse model for immune-competent studies in drug discovery, biomarker development, genetic research, and metastasis
Receive your quote directly from the manufacturer.
The KPC C57BL/6 cell line is derived from spontaneous pancreatic tumours of the Kras^G12D/+; Trp53^R172H/+; Pdx1-Cre genetically engineered KPC mouse model and backcrossed onto the immunocompetent C57BL/6 background. It retains both driver mutations — KRAS^G12D and TP53^R172H — which are among the most common genetic alterations in human pancreatic ductal adenocarcinoma (PDA).
When implanted orthotopically or subcutaneously into immunocompetent C57BL/6 mice, this line produces robust, reproducible tumours reminiscent of human pancreatic cancer.
Key features
- Endogenous KRAS^G12D and TP53^R172H mutations reflecting human PDA genetics
- Fully congenic on the C57BL/6 background following ten generations of backcrossing
- Reliable orthotopic and subcutaneous tumour formation in immunocompetent hosts
Applications
- Preclinical drug discovery
- Biomarker identification and validation
- Genetic research
- Metastasis modelling
- Immuno-oncology research, including evaluation of KRAS dependency and tumour–immune interactions
